ABCG2 and Miyoshi myopathy: In this regard, we focused on a combination of a conventional drug against MM with targeted ABCG2 ability as well as a UTMD technique to design an exciting therapeutic strategy for the treatment of the refractory disease in MM-bearing NOD/SCID mice.